NCGC00244536 (also known as KDM4B Inhibitor B3; KDM4B-IN-B3) is a novel and potent inhibitor of the Histone lysine demethylase KDM4 with an IC50 of 10 nM.

Iadademstat (ORY-1001; RG6016) 2HCl, the dihydrochloride salt of ORY1001, is a novel, orally bioactive and selective lysine-specific demethylase LSD1/KDM1A inhibitor with antineoplastic activity.

Seclidemstat (formerly also known as SP-2577; SP2577) is a novel, potent small molecule inhibitor of epigenetic enzyme LSD1 (lysine-specific demethylase 1) with anticancer activity.

GSK-LSD1 2HCl, the dihydrochloride salt of GSK-LSD1 (GSK-LSD-1), is an irreversible, potent and selective inhibitor of Lysine (K) -specific demethylase 1A (LSD1) with antineoplastic activity.

Pulrodemstat besylate (formerly CC-90011 besylate; LSD1-IN-7), the besylate salt of CC-90011 (LSD1-IN7; CC90011), is a highly potent and orally bioavailable inhibitor of lysine specific demethylase-1 (LSD1) with potential anticancer activity.

KDM5-IN-48 is a novel, potent, selective and orally bioavailable KDM5 inhibitor (IC50 o=15.1 nM).

GSK2879552 (GSK-2879552) is a novel, potent and orally bioavailable, irreversible inhibitor of lysine specific demethylase 1 (LSD1) with potential anticancer activity.

GSK J4 is a novel, cell permeable, and potent prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase (KDM) JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and is inactive against a panel of demethylases of the JMJ family.